Phase 3 N=4,200 Telephone Counseling and the Distribution of Nicotine Patches to Smokers
Smoking Cessation
Primary: Number of Participants With Six-month Continuous Abstinence From Cigarettes — 70; 101; 190 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=550 A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)
Schizophrenia
Primary: Percent Change From Baseline in Body Weight at Week 24 — 6.59; 4.21 Percent change in body weight — p=0.003
Phase 3 N=58 Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical Hemolytic Uremic Syndrome (aHUS)
Primary: Percentage Of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26 — 53.6; 83.9; 76.8; 58.9 percentage of participants
Phase 3 N=322 A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder
Bipolar I Disorder · Manic Episode
Primary: Change From Baseline In Young-Mania Rating Scale (YMRS) Score At Week 3 — -10.6; -10.8 units on a scale — p==0.8797
Phase 3 N=51 A Long-term Safety Study of QMF149 in Japanese Participants With Asthma
Asthma
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 40; 0 Participants
Phase 3 N=201 Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
Papillomavirus Infections · Uterine Cervical Neoplasms · Vulvar Neoplasms
Primary: Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7 — 100; 100; 100; 100.0 Percentage of Participants
Phase 3 N=48 EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes
Type 1 Diabetes
Primary: Change in Insulin Sensitivity — 12.2; -2.4 (mg/kg/min)/(insulin) — p=0.005
Phase 3 N=1,219 Botswana TDF/FTC Oral HIV Prophylaxis Trial
HIV Infections
Primary: Percentage of Participants With Adverse Drug Reactions in the Tenofovir/Emtricitabine and Placebo Arms — 91.2; 88.2 percentage of participants with AE — p=0.003
Phase 3 N=4,209 Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines
Tetanus · Acellular Pertussis · Diphtheria
Primary: Geometric Mean Concentrations (GMCs) for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies in a Subset of Subjects — 16.704; 18.658; 18.437; 18.112 IU/mL
Phase 3 N=440 Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the Knee
Osteoarthritis
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 Pain (Walking Pain) Subscale Score Over 26 Weeks — -2.271; -2.146 score…
Phase 3 N=117 Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Refractory Generalized Myasthenia Gravis
Primary: Count Of Participants With Treatment-Emergent Adverse Events — 55; 59; 3; 5 Participants
Phase 3 N=177 Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects
Hepatitis C · HCV
Primary: SVR After G/P 12 Wks (Arm A) vs. G/P Given for 16 Weeks (Arm B) to Non-cirrhotic Treatment-experienced GT1 HCV Participants — 70; 46; 8; 3 Participants
Phase 3 N=400 Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)
Pneumococcal Infections
Primary: Percentage of Participants With an Adverse Event (AE) — 89.9; 84.4 Percentage of participants
Phase 3 N=306 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Asthma
Primary: Percentage of Participants With First Clinically Significant Exacerbation in Part C — 31.8; 20.2; 49.3; 32.3 Percentage of participants — p=0.004
Phase 3 N=370 In-Office Tympanostomy Tube Placement in Children (OTTER)
OME - Otitis Media With Effusion · AOM - Acute Otitis Media
Primary: Procedural Success: — 103; 91 Participants